Propella develops innovative, best-in-class therapeutics with an eye toward mitigated development risk. We use proven science, a novel approach, and development insight to produce products that are smarter, safer, and more effective.
We are a privately held development-stage company dedicated to bringing to market best-in-class drugs that utilize an active ingredient with a known mechanism of action. Our lead product candidate, PRL-02, is currently in a phase 1 dose-escalation study for metastatic prostate cancer. Topical CGS-200-5 has been developed for the management of knee pain due to osteoarthritis (OA) and is Phase 3 ready, having successfully completed a predictive Phase 2 study. We are actively advancing additional oncology therapies through our discovery process.
Both PRL-02 and CGS-200-5 product candidates are covered by issued US patents that are wholly owned by Propella.